Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda

References

• Brinton LA, Sherman ME, Carreon JD, Anderson WF. Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst. 2008;100(22):1643–1648.
   Google Scholar
• Fitzmaurice C, Akinyemju TF, Al Lami FH, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016. A systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568. doi:10.1001/jamaoncol.2018.2706
   PubMed Web of Science ®Google Scholar
• Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 2010;12(4):S8. doi:10.1186/bcr2737
   Web of Science ®Google Scholar
• El Saghir NS, Khalil MK, Eid T, et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int J Surg. 2007;5(4):225–233. doi:10.1016/j.ijsu.2006.06.015
   Google Scholar
• Chouchane L, Boussen H, Sastry KS. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol. 2013;14(10):e417–e424. doi:10.1016/S1470-2045(13)70165-7
   PubMed Web of Science ®Google Scholar
• Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (< 35 years) with operable breast cancer. Ann Oncol. 2010;21(10):1974–1981.
   Web of Science ®Google Scholar
• Azim HA, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;16(4):427. doi:10.1186/s13058-014-0427-5
   PubMed Web of Science ®Google Scholar
• Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208(3):341–347. doi:10.1016/j.jamcollsurg.2008.12.001
   Web of Science ®Google Scholar
• Mbonde MP, Amir H, Schwartz-Albiez R, Akslen LA, Kitinya JN. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania. Oncol Rep. 2000;7(2):277–360.
   Web of Science ®Google Scholar
• Rambau P, Masalu N, Jackson K, Chalya P, Serra P, Bravaccini S. Triple negative breast cancer in a poor resource setting in North-Western Tanzania: a preliminary study of 52 patients. BMC Res Notes. 2014;7(1):399. doi:10.1186/1756-0500-7-399
   Google Scholar
• Mwakigonja AR, Lushina NE, Mwanga A. Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania. Infect Agent Cancer. 2017;12(1):60. doi:10.1186/s13027-017-0170-5
   Web of Science ®Google Scholar
• Bird P, Hill A, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease? Ann Surg Oncol. 2008;15(7):1983. doi:10.1245/s10434-008-9900-7
   Web of Science ®Google Scholar
• Roy I, Othieno E. Breast carcinoma in Uganda: microscopic study and receptor profile of 45 cases. Arch Pathol Lab Med. 2011;135(2):194–199.
   Web of Science ®Google Scholar
• Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A. Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African population. Pan Afr Med J. 2014;17:249–330. doi:10.11604/pamj.2014.17.249.3305
   Google Scholar
• Meyer JS, Alvarez C, Milikowski C et al. Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Modern Pathology. 2015;18:1067–1078.
   Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18–43.
   PubMed Web of Science ®Google Scholar
• Adjei EK, Owusu‐Afriyie O, Awuah B, Stalsberg H. Hormone receptors and Her2 expression in breast cancer in Sub-Saharan Africa. A comparative study of biopsies from Ghana and Norway. Breast J. 2014;20(3):308–311. doi:10.1111/tbj.12261
   Web of Science ®Google Scholar
• Salhia B, Tapia C, Ishak EA, et al. Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology. BMC Women’s Health. 2011;11(1):44. doi:10.1186/1472-6874-11-44
   Web of Science ®Google Scholar
• Awadelkarim K, Arizzi C, Elami E, et al. Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology. 2008;52(4):445–456. doi:10.1111/j.1365-2559.2008.02966.x
   Web of Science ®Google Scholar
• Albrektsen G, Heuch I, Thoresen SØ. Histological type and grade of breast cancer tumors by parity, age at birth, and time since birth: a register-based study in Norway. BMC Cancer. 2010;10(1):226. doi:10.1186/1471-2407-10-226
   Web of Science ®Google Scholar
• Kennedy S, O’Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast cancer. Br J Cancer. 2003;88(7):1077–1083.
   Web of Science ®Google Scholar
• Babu GR, Samari G, Cohen SP, et al. Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev. 2011;12(7):1647–1655.
   PubMedGoogle Scholar
• Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4(11):e7695. doi:10.1371/journal.pone.0007695
   PubMed Web of Science ®Google Scholar
• Ntekim A, Nufu F, Campbell O. Breast cancer in young women in Ibadan, Nigeria. Afr Health Sci. 2009;9(4):242–246.
   Web of Science ®Google Scholar
• Chu KC, Anderson WF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat. 2002;74(3):199–211. doi:10.1023/A:1016361932220
   Web of Science ®Google Scholar
• Ikpatt O, Ndoma-Egba R. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients. Cent Afr J Med. 2003;49(11):122–126.
   Google Scholar
• Stierer M, Rosen H, Weber R, Hanak H, Spona J, Tüchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg. 1993;218(1):13. doi:10.1097/00000658-199307000-00004
   PubMed Web of Science ®Google Scholar
• Bansal C, Sharma A, Pujani M, et al. Correlation of hormone receptor and human epidermal growth factor Receptor-2/neu expression in breast cancer with various clinicopathologic factors. Indian J Med Paediatr Oncol. 2017;38(4):483. doi:10.4103/ijmpo.ijmpo_98_16
   PubMed Web of Science ®Google Scholar
• Purdie C, Quinlan P, Jordan L, et al. Pro gesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer. 2014;110(3):565–572.
   PubMed Web of Science ®Google Scholar
• Nguyen VH, Lawrence HJ. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol. 2004;22(4):1767–1769. doi:10.1200/JCO.2004.99.298
   Web of Science ®Google Scholar
• Liu Y, Gao H, Marstrand TT, et al. The genome landscape of ERα-and ERβ-binding DNA regions. Proc Natl Acad Sci U S A. 2008;105(7):2604–2609. doi:10.1073/pnas.0712085105
   Web of Science ®Google Scholar
• Lobbezoo DJ, van Kampen RJ, Voogd RJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–514. doi:10.1007/s10549-013-2711-y
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295(21):2492–2502. doi:10.1001/jama.295.21.2492
   PubMed Web of Science ®Google Scholar
• Tryggvadottir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breast cancer risk factors and age at diagnosis: an Icelandic cohort study. Int J Cancer. 2002;98(4):604–608. doi:10.1002/ijc.10217
   Web of Science ®Google Scholar
• Baum JE, Sung KJ, Tran H, Song W, Ginter PS. Mammary epithelial-myoepithelial carcinoma: report of a case with HRAS and PIK3CA mutations by next-generation sequencing. Int J Surg Pathol. 2019;27(4):441–445. doi:10.1177/1066896918821182
   Web of Science ®Google Scholar
• Wang J, Sang D, Xu B, et al. Value of breast cancer molecular subtypes and Ki67 expression for the prediction of efficacy and prognosis of neoadjuvant chemotherapy in a Chinese population. Medicine. 2016;95(18):234–241.
   Web of Science ®Google Scholar
• Kolečková M, Kolář Z, Ehrmann J, Kořínková G, Trojanec R. Age-associated prognostic and predictive biomarkers in patients with breast cancer. Oncol Lett. 2017;13(6):4201–4207. doi:10.3892/ol.2017.6000
   Web of Science ®Google Scholar
• Arias VEA, Gobbi H, Ioshii SO, et al. Assessment of HER-2 status in invasive breast cancer in Brazil. Revista Da Associação Médica Brasileira. 2017;63(7):566–574. doi:10.1590/1806-9282.63.07.566
   Web of Science ®Google Scholar
• Rao C, Shetty J, Prasad HK. Morphological profile and receptor status in breast carcinoma: an institutional study. J Cancer Res Ther. 2013;9(1):44. doi:10.4103/0973-1482.110358
   Web of Science ®Google Scholar
• Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;5(3):421–431.
   Google Scholar
• Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423–428. doi:10.1007/s10549-008-0086-2
   PubMed Web of Science ®Google Scholar
• Nalwoga H, Arnes J, Wabinga H, Akslen L. Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. Br J Cancer. 2010;102(2):369–375. doi:10.1038/sj.bjc.6605488
   Web of Science ®Google Scholar
• Wang B, Wang X, Zou Y. Association between hormone receptors and HER-2/neu is age-related. Int J Clin Exp Pathol. 2015;8(7):8472.
   Web of Science ®Google Scholar
• Salman O, Alok Kumar D, Anthony LN, Andres A, Gayathri N. Prognostic impact of age at diagnosis in triple negative breast cancer: analysis of 204 patients from single institution registry. J Clin Oncol. 2018;36(15):154–156.
   Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA - J Am Med Assoc. 2019;321:288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann Oncol. 2007;18:70–73. doi:10.1093/annonc/mdm229
   PubMed Web of Science ®Google Scholar